Company Overview
Pulsenmore Ltd. engages in the provision of self-scan ultrasound devices designed for remote clinical diagnosis and screening operations within Israel and Europe. The company offers a specific product line comprising the Pulsenmore home ultrasound system, which utilizes a handheld ultrasound cradle dock connected to the patient's smartphone, alongside a mobile application for uploading images. This business operates within the Healthcare sector, specifically targeting the Medical Devices industry, where innovation in diagnostic technology is critical for expanding access to medical imaging. The company's scale is defined by a market capitalization of $23.41M and an employee count of 58 individuals. These valuation and staffing figures indicate that Pulsenmore Ltd. is a small-cap entity with a relatively lean operational structure, suggesting a focused business model that relies heavily on the strategic deployment of its proprietary hardware and software rather than a massive workforce or extensive asset base.
Financial Health
The company reports N/A for both annual revenue and net income, while its EBITDA stands at $-40,888,000. Although specific revenue and net income figures are not disclosed in the current data, the substantial negative EBITDA reveals a significant gap between operational revenue generation and the costs required to sustain operations, indicating a cost structure that currently exceeds gross profitability. The free cash flow is reported at $-19,023,376, which signifies that the company is burning cash at a rapid pace and lacks the financial flexibility to fund capital expenditures or strategic acquisitions without external financing. Regarding margins, the gross margin is 37.4%, suggesting that the company retains a healthy portion of revenue after direct costs, while both the operating margin and profit margin are 0.0%, indicating that overhead expenses and taxes have eroded all operational profits to the point of breakeven or loss. The company's cash position is listed as N/A, while debt is also N/A, yet the debt-to-equity ratio is 2.17, implying a highly leveraged balance sheet where liabilities significantly exceed equity. Despite the leverage, the current ratio is 7.98, which indicates strong short-term liquidity and an ability to cover current liabilities with current assets many times over. Finally, the return on equity is -45.9% and the return on assets is -19.0%, revealing that management effectiveness is currently negative, as the company is generating losses that reduce shareholder value and asset utility.
Valuation Assessment
Pulsenmore Ltd. has a P/E ratio (TTM) of N/A and a forward P/E of N/A, meaning that traditional earnings-based valuation metrics are unavailable due to the absence of reported net income. The price-to-book ratio is N/A, and the price-to-sales ratio is also N/A, preventing a direct comparison of the stock's price against its underlying book value or revenue multiples. Additionally, the EV/EBITDA is N/A, suggesting that investors must rely on alternative metrics or cash-flow-based approaches to assess the company's relative value. In terms of trading range, the 52-week high is $10.28 and the 52-week low is $3.51, indicating a wide price dispersion over the past year. The beta value is 0.23, which means the stock exhibits low volatility relative to the broader market and tends to move less than the market average during periods of price fluctuation. Without earnings data to calculate a trailing P/E, the valuation assessment relies heavily on the price range and the low beta, which suggests the stock may be less sensitive to macroeconomic shifts but carries higher idiosyncratic risk given its small market cap.
Growth & Income
The revenue growth year-over-year is -8.1%, while earnings growth is N/A due to the lack of reported net income. The negative revenue growth indicates a contraction in sales, and without earnings data to compare, it is impossible to determine if earnings are growing faster or slower than revenue, though the negative revenue trend implies a challenging top-line environment. Regarding dividends, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the company is not a dividend payer. Consequently, Pulsenmore Ltd. reinvests its limited earnings or capital reserves into growth initiatives rather than distributing cash to shareholders, a common strategy for small-cap medical device firms in their early or expansion phases. The overall growth and income profile is characterized by declining revenue and a complete absence of dividend income, reflecting a capital-intensive growth strategy that prioritizes product development and market penetration over immediate shareholder returns or financial stability.